TITLE

Rate of Clinically Significant Postoperative Pancreatic Fistula in Pancreatic Neuroendocrine Tumors

AUTHOR(S)
Inchauste, Suzanne; Lanier, Brock; Libutti, Steven; Phan, Giao; Nilubol, Naris; Steinberg, Seth; Kebebew, Electron; Hughes, Marybeth
PUB. DATE
July 2012
SOURCE
World Journal of Surgery;Jul2012, Vol. 36 Issue 7, p1517
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: In 2005, the International Study Group of Pancreatic Fistula (ISGPF) developed a definition and grading system for postoperative pancreatic fistula (POPF). The authors sought to determine the rate of POPF after enucleation and/or resection of pancreatic neuroendocrine tumors (PNET) and to identify clinical, surgical, or pathologic factors associated with POPF. Methods: A retrospective analysis of pancreatic enucleations and resections performed from March 1998 to April 2010. We defined a clinically significant POPF as a grade B that required nonoperative intervention and grade C. Results: One hundred twenty-two patients were identified; 62 patients had enucleations and 60 patients had resections of PNET. The rate of clinically significant POPF was 23.7 % (29/122). For pancreatic enucleation, the POPF rate was 27.4 % (17/62, 14 grade B, 3 grade C). The pancreatic resection group had a POPF rate of 20 % (12/60, 10 grade B, 2 grade C). This difference was not significant ( p = 0.4). In univariate analyses, patients in the enucleation group with hereditary syndromes ( p = 0.02) and non-insulinoma tumors ( p = 0.02) had a higher POPF rate. Patients in the resection group with body mass index (BMI) > 25 ( p < 0.01), multiple endocrine neoplasia type 1 (MEN-1; p < 0.01) and those who underwent simultaneous multiple procedures ( p = 0.02) had a higher POPF rate. Multivariate analyses revealed that hereditary syndromes were able to predict POPF in the enucleation group, while having BMI > 25 and increasing lesion size were also associated with POPF in the group undergoing resection. Conclusions: We found a clinically significant POPF rate after surgery in PNET to be 23.7 % with no difference by the type of operation. Our POPF rate is comparable to that reported in the literature for pancreatic resection for other types of tumors. Certain inherited genetic diseases-von Hippel-Lindau disease (VHL) and MEN-1-were associated with higher POPF rates.
ACCESSION #
76350190

 

Related Articles

  • Sunitinib.  // Reactions Weekly;12/2/2016, Vol. 1630 Issue 1, p228 

    An abstract of the article "Use of Sunitinib in a 30-Year-Old Woman With Pancreatic Neuroendocrine Tumors Associated With Von Hippel-Lindau Syndrome" by W. Wang and others is presented.

  • Nervous system involvement in von Hippel-Lindau disease: pathology and mechanisms. Vortmeyer, Alexander; Falke, Eric; Gläsker, Sven; Li, Jie; Oldfield, Edward // Acta Neuropathologica;Mar2013, Vol. 125 Issue 3, p333 

    Patients with von Hippel-Lindau disease carry a germline mutation of the Von Hippel-Lindau (VHL) tumor-suppressor gene. We discuss the molecular consequences of loss of VHL gene function and their impact on the nervous system. Dysfunction of the VHL protein causes accumulation and activation of...

  • Clinical presentation of Von Hippel Lindau syndrome type 2B associated with VHL p.A149S mutation in a large Turkish family. Mete, T.; Berker, D.; Yilmaz, E.; Ozgen, G.; Yalcin, Y.; Tuna, M.; Ciliz, D.; Onen, M.; Aydin, Y.; Guler, S. // Endocrine (1355008X);Feb2014, Vol. 45 Issue 1, p128 

    Von Hippel Lindau (VHL) syndrome is an autosomal dominant disorder characterized by benign and malignant tumors. This study presents the clinical and genetic features of VHL syndrome in a Turkish family. For the diagnosis of pheochromocytoma-related diseases, 49 family members from three...

  • Neurofibromatosis 1 with pheochromocytoma. Kumar, K. V. S. Hari; Shaikh, Altamash; Sandhu, A. S.; Prusty, P. // Indian Journal of Endocrinology & Metabolism;Oct2011 Supplement, pS406 

    Von Hippel--Lindau (VHL) disease includes a wide spectrum of highly vascular tumors like pheochromocytoma, cysts and adenomas of the pancreas and kidney, endolymphatic sac and renal cell carcinoma. Molecular analysis of the VHL gene is vital in these patients and their kindred. Neuroendocrine...

  • Von Hippel-Lindau Disease: A New Approach to an Old Problem. Tootee, Ali; Hasani-Ranjbar, Shirin // International Journal of Endocrinology & Metabolism;Autumn2012, Vol. 10 Issue 4, p619 

    Background: Von Hippel-Lindau (VHL) disease is a hereditary, autosomal dominant syndrome which is manifested by a range of different benign and malignant tumors. This disease can present with different clinical presentations such as; retinal angioma (RA), hemangioblastoma (HB) of the central...

  • Update on Paragangliomas and Pheochromocytomas. LAM, Alfred K. Y. // Turkish Journal of Pathology;Jul2015 Supplement, Vol. 31, p105 

    Genomic studies in the recent decades lead to the identification of new genetic mutations that have been shown to play detrimental roles in the formation of pheochromocytoma or paraganglioma. The majority of these genetic mutations detected affect two major cellular pathways - pseudo hypoxic...

  • Diagnosis and management of pancreatic neuroendocrine tumor in von Hippel-Lindau disease. Kenji Tamura; Isao Nishimori; Tetsuhide Ito; Ichiro Yamasaki; Hisato Igarashi; Taro Shuin // Annals of Gastroenterology & Hepatology;2010, Vol. 8 Issue 89, p4515 

    The pancreatic manifestations seen in patients with von Hippel-Lindau (VHL) disease are subdivided into 2 categories: pancreatic neuroendocrine tumors (NET), and cystic lesions, including simple cyst and serous cystadenoma. The VHL-associated cystic lesions are generally asymptomatic and do not...

  • Pancreatic Lesions in von Hippel-Lindau Disease? A Systematic Review and Meta-synthesis of the Literature. Charlesworth, Michael; Verbeke, Caroline; Falk, Gavin; Walsh, Matthew; Smith, Andrew; Morris-Stiff, Gareth // Journal of Gastrointestinal Surgery;Jul2012, Vol. 16 Issue 7, p1422 

    Background: von Hippel-Lindau (vHL) disease is a rare condition that leads to characteristic lesions within many different body systems. Pancreatic manifestations of vHL cover a wide spectrum of pathologies, and thus, accurate characterization and management is critical. Methods: A comprehensive...

  • Laparoscopic Organ-Sparing Resection of Von Hippel-Lindau Disease-Associated Pancreatic Neuroendocrine Tumors. von Dücker, Laura; Walz, Martin K.; Voss, Christian; Arnold, Georg; Eng, Charis; Neumann, Hartmut P. H. // World Journal of Surgery;Mar2011, Vol. 35 Issue 3, p563 

    Background: Pancreatic neuroendocrine tumors (PNETs) are a characteristic feature of the tumor syndromes multiple endocrine neoplasia type 1 (MEN-1) and von Hippel-Lindau disease (VHL). With VHL, about 10% of the patients exhibit PNETs by age 40 years. Metastatic potential is high if the tumors...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics